


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original): A compound of formula (I)



(I)

wherein

-X- is  $-C(R^4R^5)-$ , -O- or -S-;


n is 2 or 3;

R<sup>1</sup> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>3</sup> is H, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), nitrile, phenyl or substituted phenyl;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from H or C<sub>1</sub>-C<sub>4</sub> alkyl;

Ar- is selected from the group consisting of



in which

R<sup>2a</sup> is H, halo, methyl or ethyl;

R<sup>2b</sup> is H, halo or methyl;

R<sup>2c</sup> is H, halo, methyl, trifluoromethyl, nitrile or methoxy;

R<sup>2d</sup> is H, halo, methyl or ethyl;

R<sup>2e</sup> is H, halo, methyl, trifluoromethyl, nitrile or methoxy;


R<sup>2f</sup> is H, or fluoro;

-Y- is -O-, -S- or -N(R<sup>6</sup>)-; and

R<sup>6</sup> is H or methyl;

or a pharmaceutically acceptable salt thereof.


2. (original): A compound as claimed in claim 1, represented by the formula (Ia)



(Ia)

wherein -X-, n, R<sup>1</sup>, R<sup>3</sup> and Ar have the values as defined for formula (I) in claim 1.

3. (currently amended): A compound as claimed in ~~either~~ claim 1 ~~or~~ 2, wherein -X- is -C(R<sup>4</sup>R<sup>5</sup>)-.
4. (original): A compound as claimed in claim 3, wherein R<sup>4</sup> and R<sup>5</sup> are both H.
5. (original): A compound as claimed in claim 3, wherein R<sup>4</sup> and R<sup>5</sup> are both the same C<sub>1</sub>-C<sub>4</sub> alkyl.
6. (currently amended): A compound as claimed in ~~any one of claims 1 to 5~~ claim 1, wherein Ar is (i).
7. (original): A compound as claimed in claim 6, wherein R<sup>2c</sup> is H.
8. (currently amended): A compound as claimed in ~~either~~ claim 6 ~~or~~ 7, wherein R<sup>2a</sup> is H or methyl, R<sup>2b</sup> is H and R<sup>2f</sup> is H.
9. (currently amended): A compound as claimed in ~~either~~ claim 6 ~~or~~ 7, wherein R<sup>2a</sup> is H, R<sup>2b</sup> is halo and R<sup>2f</sup> is H or fluoro.
10. (currently amended): A compound as claimed in ~~any one of claims 1 to 5~~ claim 1, wherein Ar is (ii) and -Y- is -S-.
11. (currently amended): A compound as claimed in ~~any one of claims 1 to 4~~ claim 1, represented by the formula II



(II)

wherein  $n$ ,  $R^1$ ,  $R^{2a}$  and  $R^{2b}$  have the values as defined for formula (I) in claim 1 and  $R^3$  is H, halo, phenyl or substituted phenyl.

12. (currently amended): A compound as claimed in ~~any one of claims 1 to 11~~ claim 1, wherein  $n$  is 3.
13. (currently amended): A compound as claimed in ~~any one of claims 1 to 12~~ claim 1, wherein  $R^1$  is H, methyl, ethyl or  $n$ -propyl.
14. (currently amended): A compound as claimed in ~~any one of claims 1 to 13~~ claim 1, wherein  $R^3$  is H or halo.
15. (currently amended): A pharmaceutical composition comprising a compound as claimed in ~~any one of claims 1 to 14~~ claim 1 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
16. (canceled)
17. (canceled)
18. (canceled)
19. (currently amended): A method for selectively inhibiting the reuptake of norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims 1 to 14~~ claim 1, or a pharmaceutically acceptable salt thereof.

20. (currently amended): A method for treating ~~disorders~~ a disorder associated with norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims 1 to 14~~ claim 1, or a pharmaceutically acceptable salt thereof.
21. (new): A method as claimed in claim 20, wherein said disorder is selected from the group consisting of an addictive disorder and withdrawal syndrome, an adjustment disorder, an age-associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder (ADD) due to general medical conditions, attention-deficit hyperactivity disorder (ADHD), bipolar disorder, bulimia nervosa, chronic fatigue syndrome, chronic or acute stress, conduct disorder, cyclothymic disorder, depression, dysthymic disorder, fibromyalgia and other somatoform disorders, generalized anxiety disorder, incontinence, an inhalation disorder, an intoxication disorder, mania, migraine headaches, obesity, obsessive compulsive disorders and related spectrum disorders, oppositional defiant disorder, panic disorder, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder, seasonal affective disorder, a sleep disorder, social phobia, a specific developmental disorder, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome, TIC disorders, cognitive disorders including mild cognitive impairment (MCI), dementia of the Alzheimers type (DAT), vascular dementia and cognitive impairment associated with schizophrenia (CIAS), hypotensive states including orthostatic hypotension, and pain including chronic pain, neuropathic pain and antinociceptive pain.
22. (new): A method as claimed in claim 21, wherein said disorder is attention-deficit hyperactivity disorder (ADHD).